Study shows Lucid's EsoGuard test detects esophageal precancer in at-risk patients without symptoms. Read more here.

Lucid Diagnostics (LUCD) announced positive data from a National Cancer Institute-sponsored study demonstrating that its EsoGuard Esophageal ...

These results support EsoGuard esophageal precancer testing in an expanded target population, consistent with existing American Gastroenterological Association (AGA) guidelines and has the ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced ...

Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing For more information about Lucid, please visit www.luciddx.com and for more information about ...

(RTTNews) - Lucid Diagnostics Inc. (LUCD), a subsidiary of PAVmed Inc. (PAVM), Thursday reported positive data from a National Cancer Institute (NCI)-sponsored study of its EsoGuard Esophageal DNA ...

A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval.